GlassScriptPhysician profile
Khawar A Chaudhry
NPI 1538422548
$2,861.69
in general payments reported to CMS, 2019-2025
31 companies · $609 in 2025
The $609 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $110 · 2021: $247 · 2022: $585 · 2023: $748 · 2024: $349 · 2025: $609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,706.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,705.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $383.34 | 2021-2025 | Vraylar, Ubrelvy, Linzess |
| Indivior INC. | $314.81 | 2019-2025 | Sublocade |
| Uswm, LLC | $230.32 | 2022-2024 | Lucemyra, Zimhi |
| Avanir Pharmaceuticals, INC. | $193.00 | 2019-2022 | |
| Itamar Medical INC | $185.06 | 2023 | Watchpatone |
| Orexo US, INC. | $178.03 | 2020-2024 | Zubsolv |
| Ucb, INC. | $169.56 | 2023-2025 | Nayzilam |
| Gilead Sciences, INC. | $136.39 | 2025 | |
| Glaxosmithkline, LLC. | $111.10 | 2020-2022 | |
| Axsome Therapeutics, INC. | $103.50 | 2022-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $91.97 | 2023-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $85.48 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $74.64 | 2022-2025 | Rexulti |
| Lilly USA, LLC | $63.92 | 2023-2025 | Mounjaro, Zepbound |
| Lundbeck LLC | $63.63 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $62.27 | 2024-2025 | Brixadi |
| Allergan, INC. | $58.31 | 2020 | |
| Alkermes, INC. | $49.46 | 2022-2025 | Vivitrol |
| Takeda Pharmaceuticals U.S.A., INC. | $49.41 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $38.43 | 2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $33.26 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.82 | 2022-2025 | Xifaxan |
| Pfizer INC. | $27.87 | 2019-2023 | |
| Phathom Pharmaceuticals, INC. | $20.60 | 2025 | Voquezna |
| Antares Pharma, INC. | $18.71 | 2022 | |
| Shield Therapeutics INC | $16.26 | 2022 | |
| Ardelyx, INC. | $16.06 | 2024 | Ibsrela |
| Dexcom, INC. | $14.94 | 2023 | Dexcom G6 Transmitter |
| Evoke Pharma, INC. | $14.14 | 2023 | Gimoti |
| Xeris Pharmaceuticals, INC. | $13.24 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khawar Chaudhry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.